Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.29 ▼ -0.22
(-14.57%)
MKT CAP: $24.1M • VOL: 263.7K
52W L $1 52W H $8
BSEM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $47.5M | $69.7M |
| YoY Revenue Growth % | -31.8% | — |
| Gross Profit | $44.4M | $55.9M |
| Gross Margin % | 93.6% | 80.3% |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$689.1K | $31.1M |
| Operating Margin % | -1.5% | 44.7% |
| Net Income (GAAP) | -$6.6M | $31.0M |
| EBITDA (Normalized) | $2.0M | $31.5M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | $9.9M | $24.5M |
| Capital Expenditures (CapEx) | $3.4M | $426.6K |
| Free Cash Flow (FCF) | $6.6M | $24.0M |
| FCF Margin % | 13.9% | 34.5% |
| Return on Invested Capital (ROIC %) | -5.7% | 95.0% |
| Cash & Short-Term Equivalents | $29.5M | $22.8M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $39.1M | $40.0M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BSEM.